SGLT2 inhibitors

Victoria SochaDiabetes and Hypertension | February 5, 2024
In those with more nephrology visits in the proceeding 12 months, the odds of SGLT2 inhibitor prescription were lower.
Read More
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | February 5, 2024
Sodium-glucose transport protein 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, block SGLT2 cotransporters in the ...
Victoria SochaDiabetes and Hypertension | February 5, 2024
During a poster session at the American Society of Nephrology Kidney Week 2022, Thomas Mavrakanas, MD, MSc, and ...
Victoria SochaDiabetes and Hypertension | February 5, 2024
Previous studies have shown that the use of sodium glucose linked transporter inhibitors (SGLT-2i) in nontransplant ...
DocWire News EditorsCardiology | May 13, 2022
Coronary Heart Disease Risk Factors and Serum Expression Analysis ...
Amit Goyal, MDCardioNerds | April 11, 2023
Editor's Note: This content was written by Amit Goyal, MD, a cardiology fellow at the Cleveland Clinic, and co-founder ...
Victoria SochaAcute Kidney Injury | April 5, 2023
Donna Shu-Han Lin, MD, and colleagues at National Taiwan University Hospital, Taipei, Taiwan, conducted a meta-analysis ...
Victoria SochaAcute Kidney Injury | May 6, 2021
Of the approximately one in 11 adults worldwide with diabetes, 90% have type 2 diabetes mellitus. Globally, the ...
DocWire News EditorsHeart Failure | May 2, 2023
The manufacturers of Jardiance (empagliflozin) accounted that the FDA has granted FastTrack status to the drug for the ...
DocWire News EditorsHeart Failure | May 2, 2023
Dapagliflozin appears safe and effective across different diuretic subgroups of heart failure patients, a new analysis ...
DocWire News EditorsCardiology | September 14, 2023
This week's edition features some drug updates: one on SGLT-2 inhibitors in type 2 diabetic patients, and another on ...
DocWire News EditorsHFSA 19 | September 14, 2023
The 2019 Heart Failure Society of America Scientific Meeting (HFSA 2019) in Philadelphia has wrapped up. DocWire News ...
DocWire News EditorsAmerican Diabetes Association Scientific Sessions 2019 | April 11, 2023
A majority of patients with type 2 diabetes mellitus, atherosclerotic cardiovascular disease, and low density ...
DocWire News EditorsCardiology | April 19, 2019
This week's edition includes some troubling findings for statins, good things happening with canagliflozin, a new add-on ...
DocWire News EditorsCardiology | April 11, 2023
Semaglutide (OZEMPIC) taken weekly as an add-on therapy to sodium-glucose cotransporter-2 (SGLT-2) inhibitors was ...
DocWire News EditorsCardiology | September 14, 2023
Canagliflozin, recently approved for the reduction of heart attack and stroke risk in type 2 diabetics with known ...
DocWire News EditorsAHA Scientific Sessions 2018 | April 28, 2023
Subodh Verma, MD, of St. Michael's Hospital and University of Toronto, talks with DocWire News about the EMPA-HEART ...
DocWire News EditorsAHA Scientific Sessions 2018 | May 2, 2023
Stephen D. Wiviott, MD, talks with DocWire News, about the results and implications from the Dapagliflozin Effect on ...
Kaitlyn D’OnofrioDiabetes | April 10, 2023
Some medications for diabetes may come with the increased odds of lower limb amputation, according to a recent study.  ...
Advertisement
Advertisement
Latest News

April 26, 2024